Cellular senescence is a stress-induced state of stable proliferative arrest in which cells stop dividing but remain metabolically active. Senescent cells are characterized by elevated senescence-associated beta-galactosidase activity, impaired DNA synthesis, and induction of key cell-cycle regulators such as p53, p21, and p16INK4A. While this arrest serves as a tumor-suppressive mechanism, the persistent accumulation of senescent cells over a lifetime becomes increasingly problematic. These cells secrete a cocktail of pro-inflammatory molecules known as the senescence-associated secretory phenotype, or SASP, which includes signaling proteins such as IL-6 and IL-8. The SASP promotes chronic, low-grade inflammation that has been implicated in neurodegeneration, osteoporosis, atherosclerosis, osteoarthritis, and fibrosis across multiple organ systems.

Current therapeutic strategies against senescence fall into two broad categories. Senolytic drugs, including both synthetic agents and naturally occurring flavonoids, selectively kill senescent cells, while senomorphics aim to suppress their harmful secretions. In addition, immunotherapeutic approaches such as CAR-T cells, natural killer cell therapies, B cell-based strategies, and senolytic vaccines have emerged as alternatives that target surface molecules highly expressed on senescent cells. However, existing senolytics suffer from limited specificity and intrinsic toxicity, constraining their long-term clinical application. This unmet need for precise and targeted interventions motivated the research team, led by investigators at Peking University Health Science Center, to search for new senescence-associated surface molecules that might serve as handles for future therapies.

The researchers began by examining PTCHD4 expression across multiple cellular models of senescence. In human fetal lung diploid fibroblasts known as 2BS cells, PTCHD4 mRNA and protein levels rose significantly under both genotoxic stress, induced by bleomycin treatment, and replicative stress from continuous cell passaging. This upregulation was accompanied by classic senescence markers: reduced EdU incorporation indicating diminished DNA synthesis, increased senescence-associated beta-galactosidase activity, elevated p53 and p21, and heightened SASP factor expression. Similar increases appeared in mouse embryonic fibroblasts, human umbilical vein endothelial cells, and adult retinal pigment epithelial cells, demonstrating that PTCHD4 elevation is a cell-type-independent and species-independent feature of senescence. The pattern also held in alveolar epithelial type II cells, the lung epithelial population critically involved in pulmonary fibrosis.

Crucially, the link between PTCHD4 and aging extended beyond cell culture. Immunohistochemical staining of lung, liver, kidney, and heart tissues from 90-week-old mice and from progeroid Zmpste24-deficient mice revealed increased PTCHD4 staining that broadly paralleled p16INK4A, a canonical senescence marker. Under normal physiological conditions, PTCHD4 is typically expressed at low or undetectable levels, as documented in public expression databases, which strengthened the hypothesis that the protein plays a specific role in senescent rather than healthy cells. Analysis of public human lung transcriptomic datasets added further weight: the proportion of PTCHD4-positive alveolar type II cells was increased in idiopathic pulmonary fibrosis samples compared with controls, and PTCHD4-positive epithelial cells, including aberrant basaloid cells enriched in fibrotic lungs, exhibited higher expression of senescence markers and increased SASP module scores than their PTCHD4-negative counterparts.

To determine whether PTCHD4 merely accompanies senescence or actively drives it, the team performed gain- and loss-of-function experiments. Mouse embryonic fibroblasts isolated from PTCHD4-knockout mice maintained their proliferative capacity until passage 14, displaying senescent characteristics only at that late stage, whereas wild-type cells underwent marked growth arrest and extensive senescence by passage 8. Conversely, overexpressing PTCHD4 in young fibroblasts was sufficient to induce senescence-associated phenotypes by early passage 5, including reduced proliferation, increased beta-galactosidase activity, and elevated p53, p16INK4A, and IL-6. PTCHD4 overexpression similarly pushed alveolar epithelial type II cells toward senescence. Together, these results establish PTCHD4 as a causal contributor to the senescence program rather than a passive bystander.

The physiological consequences of PTCHD4 loss were striking in animal models. In a D-galactose-induced aging-like mouse model, PTCHD4-deficient mice exhibited substantially higher locomotor activity, greater grip strength, and longer rotarod latency than wild-type controls, indicating improved physical performance. Serum biochemical analysis revealed no detectable impairments in liver or kidney function associated with the genetic deletion. Most notably, in natural aging conditions, PTCHD4-deficient mice showed a 25 percent increase in median lifespan, rising from 20 to 25 months. While the authors note this observation requires further study, it suggests that attenuating PTCHD4 signaling may meaningfully influence organismal longevity.

The disease relevance of these findings was tested in a bleomycin-induced pulmonary fibrosis model, a standard proxy for idiopathic pulmonary fibrosis, a devastating age-associated disorder that predominantly affects people over 50. Twenty-one days after bleomycin administration, wild-type mice showed markedly reduced forced vital capacity and static lung compliance, both indicators of deteriorating lung function. PTCHD4-deficient mice, however, retained significantly better pulmonary function. Sirius Red staining confirmed substantially lower collagen deposition in knockout lungs, and histological examination revealed less alveolar structural destruction and reduced inflammatory cell infiltration. Immunofluorescence analysis showed that p21-positive senescence signals in the alveolar epithelial compartment, along with bleomycin-induced upregulation of IL-6 and Cxcl2, were suppressed by PTCHD4 deficiency, indicating that the protein’s deletion dampens both the senescence response and the inflammatory cascade that fuels fibrotic remodeling.

Mechanistically, the study traced PTCHD4’s effects to the PI3K-AKT signaling pathway, a well-characterized regulator of aging whose persistent activation accelerates senescence through enhanced mTOR signaling, increased oxidative stress, and reinforced p53/p21- and p16/Rb-mediated cell-cycle arrest. Although PTCHD4 is structurally related to PTCH1, a known inhibitor of Hedgehog signaling, the researchers found that canonical Hedgehog target genes remained unchanged when PTCHD4 was manipulated. Transcriptome sequencing of young and old wild-type and knockout fibroblasts instead revealed significant downregulation of the PI3K-AKT pathway in old PTCHD4-deficient cells. Phosphorylated AKT at Ser473 was elevated in old wild-type fibroblasts but substantially lower in old knockout cells. Critically, re-expressing a constitutively active AKT construct in PTCHD4-deficient fibroblasts reversed the anti-senescence effects, restoring senescence markers and SASP expression, while dominant-negative AKT or pharmacological inhibition with MK-2206 phenocopied the protective effect of PTCHD4 deletion. Pull-down experiments suggest PTCHD4 does not physically bind AKT directly, pointing to an intermediate mechanism still to be discovered.

The study also clarifies how PTCHD4 itself is regulated during senescence. Previous work has shown that the tumor suppressor p53 transcriptionally activates PTCHD4, embedding it in a canonical senescence pathway, while recent research identified post-transcriptional control through METTL3/METTL14-mediated m6A modification and IGF2BP1-dependent mRNA stabilization in senescent cells. The authors acknowledge important limitations: the precise molecular cascade connecting PTCHD4 to AKT activation remains undefined, direct evidence from primary human tissue samples is still lacking, and the long-term, organ-specific consequences of PTCHD4 deletion require systematic safety assessment. Nevertheless, by linking a poorly characterized membrane protein to AKT signaling, lifespan, physical performance, and pulmonary fibrosis, the study provides a compelling foundation for exploring the PTCHD4-AKT axis as a therapeutic target. Given the growing arsenal of senescent-cell-targeting immunotherapies that depend on accessible surface molecules, a transmembrane protein upregulated specifically in senescent cells could prove an ideal candidate for future anti-aging medicine.

Subject of Research: Identification of the transmembrane protein PTCHD4 as a regulator of cellular senescence, aging, and age-related pulmonary fibrosis through AKT signaling

Article Title: Transmembrane Protein PTCHD4 Is a Novel Regulator of Cellular Senescence and Age‐Related Pathologies

Article References: Transmembrane Protein PTCHD4 Is a Novel Regulator of Cellular Senescence and Age‐Related Pathologies. (n.d.). https://doi.org/10.1111/acel.70711

Image Credits: AI Generated

DOI: 10.1111/acel.70711

Keywords: PTCHD4, cellular senescence, aging, AKT signaling, pulmonary fibrosis, SASP, senolytics, p53, lifespan, alveolar epithelial cells, patched domain family, Aging Cell